Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.68 - $2.39 $47,793 - $167,981
70,285 Added 587.57%
82,247 $55,000
Q3 2023

Nov 22, 2023

BUY
$2.15 - $3.64 $25,718 - $43,541
11,962 New
11,962 $25,000
Q3 2022

Nov 14, 2022

BUY
$4.13 - $8.79 $53,421 - $113,698
12,935 New
12,935 $102,000

Others Institutions Holding ALVR

About Allovir, Inc.


  • Ticker ALVR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,063,400
  • Market Cap $933M
  • Description
  • Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...
More about ALVR
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.